Skip to content
Bomb Report – Lifestyle
Author:
MapLight Therapeutics, Inc.
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 22, 2026
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2026
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conferences
March 6, 2026